InsiderTrades.com logo
Joseph Shulman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joseph Shulman Biography and Net Worth

Insider of Rhythm Pharmaceuticals
Joe Shulman was promoted to Chief Technical Officer in 2022. He had joined Rhythm as our Senior Vice President, Technical Operations in July 2020. Joe brings more than 20 years of industry experience and is responsible for chemistry, manufacturing, and controls (CMC), clinical and commercial supply chains, and cGMP quality assurance and quality control. Prior to joining Rhythm, Joe served as Senior Vice President of Technical Operations at Ra Pharmaceuticals, acquired by UCB in 2020, where he oversaw all aspects of CMC development, pre-commercialization supply chain planning and strategy as a member of the executive leadership team. Before that, he was senior vice president of global technical operations at Novelion Therapeutics, where he had responsibility for CMC, quality assurance, program management, patient/hub services, and global patient supply of Juxtapid® and Myalept®, two globally marketed products for rare metabolic diseases.  Earlier in his career, Joe held roles of increasing responsibility at biotechnology companies in the areas of CMC, technical operations, and program and alliance management. He holds an M.B.A. from Boston University and earned a B.S. in chemical engineering from Miami University.

What is Joseph Shulman's net worth?

The estimated net worth of Joseph Shulman is at least $462,251.43 as of February 19th, 2025. Mr. Shulman owns 8,509 shares of Rhythm Pharmaceuticals stock worth more than $462,251 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Shulman may own. Additionally, Mr. Shulman receives a salary of $677,270.00 as Insider at Rhythm Pharmaceuticals. Learn More about Joseph Shulman's net worth.

How old is Joseph Shulman?

Mr. Shulman is currently 48 years old. There are 5 older executives and no younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who is 70 years old. Learn More on Joseph Shulman's age.

What is Joseph Shulman's salary?

As the Insider of Rhythm Pharmaceuticals, Inc., Mr. Shulman earns $677,270.00 per year. There are 4 executives that earn more than Mr. Shulman. The highest earning executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who commands a salary of $1,350,000.00 per year. Learn More on Joseph Shulman's salary.

How do I contact Joseph Shulman?

The corporate mailing address for Mr. Shulman and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at hannah.deresiewicz@sternir.com. Learn More on Joseph Shulman's contact information.

Has Joseph Shulman been buying or selling shares of Rhythm Pharmaceuticals?

During the last quarter, Joseph Shulman has sold $192,058.93 in Rhythm Pharmaceuticals stock. Most recently, Joseph Shulman sold 1,228 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a transaction totalling $70,266.16. Following the completion of the sale, the insider now directly owns 8,509 shares of the company's stock, valued at $486,884.98. Learn More on Joseph Shulman's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Christopher German (CAO), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 29 times. They sold a total of 324,346 shares worth more than $17,786,121.64. The most recent insider tranaction occured on March, 21st when CAO Christopher Paul German sold 344 shares worth more than $18,655.12. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 3/21/2025.

Joseph Shulman Insider Trading History at Rhythm Pharmaceuticals

See Full Table

Joseph Shulman Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows Joseph Shulman's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$192ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $54.33
Low: $52.54
High: $54.90

50 Day Range

MA: $55.26
Low: $48.56
High: $61.02

2 Week Range

Now: $54.33
Low: $35.17
High: $68.58

Volume

278,434 shs

Average Volume

485,299 shs

Market Capitalization

$3.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3